Navigation Links
Results From Phase 2 Clinical Study of 6R-BH4 in Peripheral Arterial Disease Not Statistically Significant
Date:2/3/2009

NOVATO, Calif., Feb. 3 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced results from its Phase 2 multi-center, randomized, double-blind, placebo-controlled clinical study of 6R-BH4 in patients with symptomatic peripheral arterial disease (PAD). There was no statistical significance observed between the 6R-BH4 treatment and placebo groups.

The primary endpoint of the study, peak walking time (PWT), did not show a significant difference between 6R-BH4 and placebo, and the secondary endpoint, claudication onset time, also did not show a difference. Addition of Vitamin C to 6R-BH4 did not improve efficacy on PWT. Endothelial dysfunction evaluated by peripheral arterial tonometry in a subset of patients did not show a significant benefit with 6R-BH4. Urinary protein excretion did not decrease with 6R-BH4 treatment, though there may have been some effect in the subset of patients with microalbuminuria at baseline. 6R-BH4 was well-tolerated in peripheral arterial disease patients and had a safety profile similar to previous studies.

Emil Kakkis, M.D., Ph.D., Chief Medical Officer of BioMarin stated, "We are disappointed that the results of 6R-BH4 in peripheral arterial disease were not statistically significant. We have upcoming data in several BioMarin and investigator-sponsored studies of 6R-BH4 including proteinuria, pulmonary arterial hypertension and 6R-BH4 plus Vitamin C in patients with endothelial dysfunction. Along with the prior results in sickle cell disease, these data will determine the future of the 6R-BH4 cardiovascular program once all the studies are complete."

Study Design

The Phase 2 multi-center, randomized, double-blind, placebo-controlled study enrolled 190 subjects and was conducted at 31 sites in the U.S. and Argentina. 161 patients comple
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Webcast of QIAGEN N.V.s (Nasdaq: QGEN) Fourth Quarter and Year-End 2008 Financial Results Call Set for February 10
2. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
3. Corgenix to Host Conference Call to Discuss Second Quarter Results
4. BioMed Realty Trust to Report 2008 Fourth Quarter and Year-End Results
5. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
6. Cardica Announces Fiscal 2009 Second Quarter Financial Results
7. ThermoGenesis Corp. to Announce Second Quarter Fiscal 2009 Results on February 4, 2009
8. Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results
9. Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
10. CuraGen Reports Fourth Quarter 2008 Financial Results; Provides Milestone and Financial Guidance for First Half of 2009
11. Endo Pharmaceuticals to Announce Fourth Quarter and 2008 Full-Year Financial Results on February 27, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... BioConvergence team members Curtis Strother and ... BioLogistics Summit in San Francisco earlier this month. ... IQ and IQPC, addressed the increasingly complex logistical ... attributed to current trends of globalization, outsourcing, and ... is an increase in movement, which is often ...
(Date:6/19/2013)... Adding to their already extensive supply of ... Dropette® and Heathrow Scientific disposable plastic transfer ... biology, chemistry and any type of liquid handling analysis ... years, Simport has been supplying the science community with ... Simport Dropette®. Simport’s Dropette® is a one-piece plastic ...
(Date:6/18/2013)... Angeles, CA (PRWEB) June 18, 2013 (PRWEB) June ... construction’s #1 time and attendance system in North ... software that shares employee data and payroll records ... AccountLinx Plus automates ExakTime software setup ... The software imports employee data from a business’ ...
(Date:6/18/2013)... June 18, 2013 Nasseo, Inc. today ... Challenge Winner out of hundreds of applicants by the ... Arizona Innovation Challenge . The Arizona Innovation Challenge ... a technology commercialization challenge, granting a financial award to ... technology ventures. Nasseo’s state of the art dental and ...
Breaking Biology Technology:BioConvergence® Presents at BioLogistics Summit on Risk Matrix for Biosamples during Shipment 2Leading Pipette Distributor Pipette.com Now Stocks Transfer Pipettes: Simport’s Dropette and Heathrow Scientific Disposable Plastic Transfer Pipettes 2ExakTime Introduces AccountLinx Plus 2Nasseo Named 2013 Innovation Challenge Winner by Arizona Commerce Authority 2
... German . , Automation makes a business competitive ... small and medium-sized enterprises (SMEs). However, for many SMEs, ... too big or too expensive. SMErobot now promises to ... in small and medium-sized businesses: this EU project is ...
... 28 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc.,(NASDAQ: AEZS ... on,endocrine therapy and oncology, will announce its fourth ... market open on,Wednesday, March 5, 2008. The Company ... these results later that same day at 10:00 ...
... KOSN ) today reported financial results for the,quarter and year ... and year ended December 31, 2007 were $9.5,million and $28.7 ... and $29.5 million, or $0.13 and $0.88 per share, in ... million and $22.7 million for the quarter and year,ended December ...
Cached Biology Technology:SMErobot: A new generation of robots for small and medium-sized enterprises at Automatica 2008 2SMErobot: A new generation of robots for small and medium-sized enterprises at Automatica 2008 3SMErobot: A new generation of robots for small and medium-sized enterprises at Automatica 2008 4Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook 2Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook 3Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook 4Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook 5Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook 6
(Date:6/18/2013)... 5% and 10% of breast and ovarian cancers are ... tumours are attributable to inherited mutations from the parents ... with these mutations, PARP inhibitors, which are currently in ... a new option for personalised cancer treatment, an alternative ... a fraction of these patients generate resistance to the ...
(Date:6/18/2013)... of internationally recognized feline experts including veterinarians and feline ... of Lincoln, U.K. and Dr Ilona Rodan, Director of ... International Society of Feline Medicine (ISFM) and the American ... veterinarians, owners and those working with cats on how ... The new guidelines appear in the Journal of ...
(Date:6/17/2013)... to high levels of air pollution while pregnant were up ... as women who lived in areas with low pollution, according ... (HSPH). It is the first large national study to examine ... "Our findings raise concerns since, depending on the pollutant, 20% ... areas where risk of autism was elevated," said lead author ...
Breaking Biology News(10 mins):An article in 'Cell' reveals a new resistance mechanism to chemotherapy in breast and ovarian cancer 2Feline behavior experts release guidelines to improve the welfare of cats 2Exposure to high pollution levels during pregnancy may increase risk of having child with autism 2
... Mont. -- Natural barriers like waterfalls play an important ... National Park, so maintaining those barriers should be a ... four-year study in the park. Park workers might ... the water from rising behind those barriers, said graduate ...
... more than 300 leading European and Chinese scientists have ... in the Peoples Republic of China to present their ... Dragon 2. The Dragon Programme is a joint ... Technology (MOST) of China designed to encourage increased exploitation ...
... (April 24, 2008) The Wildlife Conservation Society (WCS) ... change is affecting populations of a quintessential Arctic denizen: ... the National Park Service, U. S. Geological Survey, and ... already equipped six musk ox with GPS collars to ...
Cached Biology News:Montana State researchers study spread of lake trout in Glacier National Park 2Successful cooperation extends Dragon Program 2Successful cooperation extends Dragon Program 3
Human MFRP MAb (Clone 291218)...
Human RELT/TNFRSF19L MAb (Clone 238104)...
...
... assay kit measures NOS activity by monitoring ... This assay is simple, sensitive, and specific ... with both crude and purified enzyme preparations. ... for 50 total reactions. Radiolabeled arginine and ...
Biology Products: